Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020

Abstract

ObjectivesTo evaluate the incremental value of new drugs across disease areas receiving favourable coverage decisions by the UK’s National Institute for Health and Care Excellence (NICE) over the past decade.Design, setting, and participantsThis cross-sectional study assessed favourable appraisal decisions of drugs between 1 January 2010 and 31 December 2020. Estimates of incremental benefit were extracted from NICE’s evidence review groups reports.Primary outcome measureIncremental benefit of novel drugs relative to the best alternative therapeutic option, expressed in quality-adjusted life-years (QALYs).Results184 appraisals of 129 drugs provided QALYs. The median incremental value was 0.27 QALY (IQR: 0.07–0.73). Benefits varied across drug-indication pairs (range: −0.49 to 5.22 QALY). The highest median benefits were found in haematology (0.70, IQR: 0.55–1.22) and oncology (0.46, IQR: 0.20–0.88), the lowest in ophthalmology (0.09, IQR: 0.04–0.22) and endocrinology (0.02, IQR: 0.01–0.06). Eight appraisals (4.3%) found contributions of more than two QALYs, but one in four (50/184) drug-indication pairs provided less than the equivalent of 1 month in perfect health compared to existing treatments.ConclusionsIn our review period, the median incremental value of novel drugs approved for use within the English National Health System, relative to the best alternative therapeutic option, was equivalent to 3–4 months of life in perfect health, but data were heterogeneous. Objective evaluations of therapeutic value helps patients and physicians to develop reasonable expectations of drugs and delivers insights into disease areas where medicinal therapeutic progress has had the most and least impact.

Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model

“…Although UK health benefits are discounted at a higher rate compared to the Netherlands, an analysis of 129 drugs approved on the National Health Service found 0.27 median incremental QALYs of new drugs relative to the best available alternative. 14 Nonetheless, EHT strategies carry a risk of overspending health care budgets as shown in the probabilistic analysis. There is a 53.8% chance that the EHT strategy produces more QALYs but at unacceptable costs.…”

Estimating Quality of Life Decrements in Oncology Using Time to Death

“…Nevertheless, compared with QALYs gained commonly seen in submissions to health technology assessment bodies, the difference is large. For example, a recent analysis of 10 years of National Institute for Health and Care Excellence submissions 34 showed that the median QALY gain in 184 appraisals was 0.27, meaning that changes in QALY estimates can have a large impact on costeffectiveness ratios.…”

NICE’s new methods: putting innovation first, but at what cost?

“…Some technologies—such as lumacaftor-ivacaftor for cystic fibrosis—might justify this opportunity cost, and society has shown itself willing to trade off some population health in the interest of fairness. But truly “game changing” innovations remain rare, with most new technologies offering only small incremental benefits 31. They might become rarer still if payers do not maintain their expectations that new products must demonstrate both clinical and cost effectiveness to be adopted.…”